Key clinical point: Targeted Lynch syndrome sequencing panel rapidly IDs Lynch syndrome pathogenic mutations.
Major finding: Lynch syndrome prevalence may be 6-7 times greater than the current estimate of 3% to 5%.
Study details: An analysis of a next-generation sequencing panel in 71 patients.
Disclosures: Dr. Padron reported having no relevant financial disclosures.
REPORTING FROM ACOG 2019